. Author manuscript; available in PMC: 2021 Apr 21.

Published in final edited form as: Int Ophthalmol Clin. 2020 Spring;60(2):77–89. doi: 10.1097/IIO.0000000000000308

Table 1.

Conjunctival Melanoma Treated by Checkpoint Inhibitor

References	Tumor Stage	Checkpoint Inhibitor	Resection Prior	Topical Therapy Prior	Radiation Prior	Metastatic Disease	Previous Systemic Therapy	Tumor Response	Follow-up	Adverse Events
Finger et al⁴¹	AJCC-T3bN0M0	Ipilimumab, then pembrolizumab	Yes	Yes		No	No	Yes	36 mo since initiation of therapy, 2y NED	Adrenal insufficiency, dermatitis
	AJCC-cT3bN0M0, pT4b	Pembrolizumab, then ipilimumab	No	No		No	No	Yes		None
	AJCC-T3bN0M0	Pembrolizumab, then combination with ipilimumab	Yes	Yes	Brachytherapy	No	No	Yes	> 18 mo	None
	M1	Ipilimumab, then pembrolizumab in combination and alone	Yes	Yes	Regional at site of metastases	Yes	No	Yes	> 24 mo
	M1	Ipilimumab, Nivolumab	Yes	Yes		Yes	No	Yes	> 36 mo	Grade II hepatotoxicity, grade III colitis, grade II pneumonitis
Sagiv et al⁴²	M1	Nivolumab	Yes	No	No	Yes	No	Yes	9 mo
	M1	Nivolumab	Yes	Yes	No	Yes	No	Yes	36
	M1	Nivolumab	Yes	No	No	Yes	Interferon	Yes	7	Colitis
	M1	Pembrolizumab, then ipilimumab	Yes	No	Yes	Yes		Yes	2	Grade IV hepatotoxicity
	M1	Nivolumab	Yes	No	No	Yes	No	Yes	1	Colitis
Kini et al⁴³	Localized disease	Pembrolizumab	Yes	No	No	No	No	Yes	12 mo
Chaves et al⁴⁴	AJCC-T3bN1M0	Ipilimumab	Yes	No	Custom iodine-125 device	Yes	No	Yes		Mild fatigue
Ford et al⁴⁵	M1	Nivolumab	Yes	Yes	No	Yes	No	Yes	~24 mo	Not addressed
Pinto Torres et al⁴⁶	M1	Pembrolizumab	Yes	No	No	Yes	No	Yes	9 mo	None noted

NED indicates no evidence of disease.